[A25-21] Cabotegravir (HIV-1 infection in adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2025
Project no.:
A25-21
Commission:
Commission awarded on 12.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adolescents (at least 12 years of age and weighing at least 35 kg) with HIV-1 infection, who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) class
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-21
| Project no. | Title | Status |
|---|---|---|
| A21-47 | Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |